

**WHI MANUALS**  
**VOLUME 2: PROCEDURES**  
**TABLE OF CONTENTS**

**SECTION 1: INTRODUCTION TO WHI**

**Introduction .....1-1**

**1.1 Overview.....1-2**

1.1.1 Clinical Trial..... 1-2

1.1.2 Observational Study ..... 1-2

**1.2 Time Table for the Clinical Trial and Observational Study .....1-3**

**1.3 WHI Manuals .....1-4**

**1.4 Study Communication.....1-5**

1.4.1 Lines of Communication..... 1-5

1.4.2 Methods of Communication ..... 1-5

**1.5 Contact with Primary Care Physicians.....1-8**

**SECTION 2: CLINICAL CENTER GUIDELINES**

**Introduction .....2-1**

**2.1 Clinical Center Facilities .....2-2**

2.1.1 Clinic Area ..... 2-2

Required Clinic Areas (Required) ..... 2-2

Recommended Clinic Areas ..... 2-2

2.1.2 Computing ..... 2-3

Preparing Facilities for WHI Computing System (Required)..... 2-3

Guidelines for Allocating Computers to Clinical Center Areas ..... 2-3

Guidelines for Data Entry Area ..... 2-4

2.1.3 Remote Sites..... 2-4

Remote Site Randomizations ..... 2-5

Remote Site Follow-Up Visits ..... 2-5

**2.2 Services (Required).....2-6**

**2.3 Equipment and Supplies.....2-7**

2.3.1 Equipment and Supplies Supplied to CCs ..... 2-7

Equipment Supplied by NIH..... 2-7

Supplies Provided by the CCC..... 2-7

Supplies Provided by McKesson BioServices ..... 2-8

Supplies Provided by EPICARE..... 2-9

Supplies Provided by Businesses or Corporations ..... 2-9

2.3.2 Equipment and Supplies CCs Must Purchase (Required)..... 2-9

Computer Equipment and Supplies ..... 2-9

DM Intervention..... 2-9

Clinical Measurement ..... 2-10

	ECG Measurements.....	2-12
	Blood and Urine Collection, Processing, and Shipment.....	2-12
	Other Equipment and Supplies.....	2-15
2.3.3	Recommended Supplies .....	2-16
<b>2.4</b>	<b>Staffing.....</b>	<b>2-19</b>
2.4.1	Clinical Center Management.....	2-19
2.4.2	Clerical and Support.....	2-19
2.4.3	Recruitment Activities .....	2-20
2.4.4	Clinical.....	2-20
2.4.5	Nutrition Interventionist .....	2-21
2.4.6	Dietary Assessment Staff.....	2-22
2.4.7	Outcome Specialist.....	2-22
2.4.8	Data Coordinator.....	2-23
<b>2.5</b>	<b>Participant Contacts .....</b>	<b>2-24</b>
2.5.1	Participant Timeline (Required).....	2-24
2.5.2	Tasks Per Participant Contact (Required).....	2-24
2.5.3	Estimating Number of Participant Contacts .....	2-25
<b>2.6</b>	<b>Activities Common To Participant Contacts .....</b>	<b>2-27</b>
<b>2.7</b>	<b>Clinical Center Checklists .....</b>	<b>2-28</b>
<b>2.8</b>	<b>Participant Files (Required).....</b>	<b>2-29</b>
2.8.1	Release of Participant Files (Required) .....	2-29
2.8.2	Description .....	2-29
2.8.3	Contents and Organization .....	2-29
<b>2.9</b>	<b>Clinical Center Internal Procedure Manual.....</b>	<b>2-30</b>
<b>2.10</b>	<b>Emergency Procedures .....</b>	<b>2-33</b>
2.10.1	Telephone Procedures.....	2-33
2.10.2	Clinical Center Emergencies.....	2-33
2.10.3	After-Hours Procedures (Required) .....	2-34
<b>2.11</b>	<b>Interviewer Procedures .....</b>	<b>2-35</b>
2.11.1	Overview.....	2-35
2.11.2	Research Project Interviewing.....	2-35
2.11.3	Interviewer Roles (Required).....	2-36
2.11.4	Interview Guidelines .....	2-38
	Interview Techniques (Required).....	2-38
	Special Situations (Required).....	2-42
	Guidelines for Suicidal Ideation (Required).....	2-43
	Guidelines for Domestic Violence (DV).....	2-45

## Figures

2.1	Projected Number of Screening Activities, Randomization, and Follow-Up Visits Per Month.....	2-26
2.2	Clinical Center Checklists.....	2-28

## Tables

2.1	Suggested Personal Computer (PC) Locations .....	2-3
-----	--	-----

**SECTION 3: RECRUITMENT**

**Introduction .....3-1**

**3.1 Overview.....3-2**

3.1.1 Clinical Coordinating Center Role in Recruitment ..... 3-2

3.1.2 Recruitment Coordination ..... 3-2

3.1.3 Recruitment Activities Data Collection ..... 3-3

3.1.4 System for Addressing Problems in Recruitment..... 3-3

3.1.5 Guidelines for Developing Recruitment Materials ..... 3-3

3.1.6 Participant Material Review Recommendations and Guidelines ..... 3-4A

**3.2 Recruitment Plan .....3-5**

3.2.1 Targeted Mass Mailings ..... 3-5

    Identification of Sources of Names ..... 3-6

    Using Sources for Preliminary Screening ..... 3-6

3.2.2 Priming the Community ..... 3-7

3.2.3 Mass Media ..... 3-7

3.2.4 Community Activities ..... 3-7

3.2.5 Medical Records ..... 3-8

**3.3 Study-Wide Recruitment Efforts .....3-9**

3.3.1 Video Tapes ..... 3-9

3.3.2 WHI Logo and Catch Phrase ..... 3-9

3.3.3 WHI Recruitment Brochure ..... 3-9

3.3.4 Slide Presentation ..... 3-10

3.3.5 Press Releases ..... 3-10

3.3.6 Public Service Announcements (PSAs) ..... 3-10

3.3.7 Spokespersons ..... 3-10

3.3.8 Television ..... 3-11

3.3.9 Print Media ..... 3-11

3.3.10 Recruitment Video ..... 3-11

3.3.11 Timeline..... 3-12

**3.4 Solicitation of Participants ..... 3-13**

3.4.1 Mass Mailings ..... 3-13

    Preparation of Initial Contact Mailing ..... 3-14

    Duplicates ..... 3-14

    Responses ..... 3-14

    Anticipated Return Rate ..... 3-14

    Processing Responses ..... 3-14

3.4.2 Mass Media ..... 3-15

3.4.3 Community Activities ..... 3-15

**3.5 Screening Contact ..... 3-16**

3.5.1 Purpose ..... 3-16

3.5.2 Phone Procedures ..... 3-16

    Role of Phone Interviewer..... 3-16

    Eligibility Phone Screen Script ..... 3-17

    Determine Preliminary Eligibility ..... 3-17

    Edit the Eligibility Phone Screen ..... 3-17

    Process the Eligibility Phone Screen ..... 3-17

3.5.3 Eligibility Screens Administered Other than by Phone ..... 3-18

**3.6 Mailing Initial Baseline Forms ..... 3-19**

3.6.1	Initial Baseline Forms.....	3-19
3.6.2	Procedures for Mailing and Processing Initial Baseline Forms.....	3-19
<b>3.7</b>	<b>Visit (SV0) .....</b>	<b>3-21</b>

### Figures

3.1	WHI Logo and Catch Phrase.....	3-23
3.2	WHI Recruitment Brochure .....	3-24

### Tables

3.1	Possible Pre-SV1 Recruitment Contacts .....	3-22
-----	---	------

---

## SECTION 4: SCREENING

---

<b>Introduction .....</b>	<b>4-1</b>
<b>4.1 Screening Visits for WHI.....</b>	<b>4-2</b>
<b>4.2 SV1.....</b>	<b>4-10</b>
4.2.1 Purpose of SV1 .....	4-10
4.2.2 Activities During SV1 (Recommended) .....	4-11
4.2.3 Preparation for SV1 .....	4-12
Two Weeks Before SV1.....	4-12
One Day Before SV1 .....	4-12
4.2.4 Guidelines for SV1 Activities.....	4-13
Reception.....	4-13
General Study Description (Required) .....	4-13
Initial (Screening) Informed Consent (Required).....	4-14
Blood Draw (Required).....	4-15
Questionnaire Review (Required).....	4-16
Current Medications and Current Supplements Inventory Review (Required).....	4-17
Physical Measurements (Required).....	4-28
Urine Collection (Bone Densitometry Sites) .....	4-29
CT Informed Consent (Required).....	4-22
Hormone Interview (Required).....	4-22
Distribute Forms to CT Participants (Recommended) .....	4-22
4.2.5 Observational Study Participants .....	4-23
OS Informed Consent (Required).....	4-23
Distribute Questionnaires to Observational Study Participant (Required).....	4-23
Completing SV1 for OS Participants (Required) .....	4-24
OS Enrollment (Required).....	4-24
4.2.6 Exit Interview.....	4-24
Schedule an Appointment for SV2 .....	4-24
Participant Handouts (Required) .....	4-24
4.2.7 Post-Visit Review .....	4-25
Blood Analysis Results (Required).....	4-25
Scanning and Key-Entry of Data from SV1 .....	4-25
<b>4.3 SV2.....</b>	<b>4-26</b>
4.3.1 Purpose of SV2 .....	4-26
4.3.2 Activities During SV2.....	4-26
4.3.3 Preparation for SV2 .....	4-27
Two Weeks Before SV2.....	4-27
One Week Before SV2 .....	4-27
Activities on the Morning of SV2.....	4-28

4.3.4	Guidelines for SV2 Activities.....	4-28
	Reception.....	4-28
	Clinical Trials Consent Form (Required).....	4-28
	Review of Questionnaires (Required).....	4-28
	SV2 Procedures.....	4-29
	Observational Study Participants.....	4-32
4.3.5	Exit Interview.....	4-32
	Schedule an Appointment for the Third Screening Visit.....	4-33
	Participant Handouts.....	4-33
4.3.6	Post-Visit Review.....	4-33
	Blood Analysis Results (Required).....	4-33
	Mammogram Results (Required).....	4-33
	Pap Smear Results (HRT) (Required).....	4-34
	Endometrial Aspiration (HRT) (Required).....	4-34
	Transvaginal Uterine Ultrasound (HRT) (As Needed).....	4-34
	Participants Whose Test Results Indicate Temporary Ineligibility (Required).....	4-34
	Participants Whose Test Results Indicate Ineligibility (Required).....	4-35
<b>4.4</b>	<b>SV3.....</b>	<b>4-36</b>
4.4.1	Purpose of SV3.....	4-36
4.4.2	Activities During SV3.....	4-36
4.4.3	Preparation for SV3 (Required).....	4-37
	Two Weeks Before SV3.....	4-37
	One Week Before SV3.....	4-37
4.4.4	Guidelines for SV3 Activities.....	4-38
	Reception.....	4-38
	Assess HRT Enrollment Pill Adherence (HRT).....	4-38
	Review <i>Form 53 – HRT Calendar</i> .....	4-38
	Complete <i>Form 10 – HRT Management and Safety Interview</i> .....	4-38
	Review <i>Form 2/3 – Eligibility Screen</i> .....	4-38
4.4.5	Pre-Randomization Discussion.....	4-38
	HRT Eligibility Discussion.....	4-39
	DM Eligibility Checklist.....	4-39
	Questionnaire Review.....	4-39
	Current Medications Update.....	4-39
	Functional Status Measures (Subsample).....	4-39
	Cognitive Assessment (HRT; Subsample).....	4-39
4.4.6	Randomize Participant (Required).....	4-39
4.4.7	Dispense Blinded Study Medications (HRT Only) (Required).....	4-40
4.4.8	Exit Interview.....	4-40
	Participants Assigned to the DM Dietary Change Group.....	4-40
	Participants Assigned to the DM Comparison Group.....	4-41
4.4.9	DM Participants Identified in 4DFR Subsample.....	4-41
4.4.10	Baseline Welcome Packet.....	4-41
	Health Care Provider Packet (Optional).....	4-42
4.4.11	Schedule Semi-Annual Follow-Up Contacts (Recommended).....	4-42
4.4.12	Participant Materials (Required).....	4-43
4.4.13	Enroll in Observational Study (OS) (Recommended).....	4-43
<b>4.5</b>	<b>Eligibility.....</b>	<b>4-44</b>
4.5.1	Determining Eligibility.....	4-44
4.5.2	Definition of Postmenopausal Status.....	4-44
	HRT Menopause Algorithms (Figure 4.8).....	4-45
	DM and OS Menopausal Algorithms (Figure 4.9).....	4-45
4.5.3	Time Limits During Screening.....	4-48
4.5.4	Rescreening Ineligible Participants.....	4-48

	Tasks to be Repeated Post-HRT Washout.....	4-48
	Ineligible on <i>Form 2/3 – Eligibility Screen</i> .....	4-49
	FFQ Rescreening.....	4-50
	Ineligible at SV1 or Later Screening Visits.....	4-52
4.5.5	Waiver of an Eligibility Criterion.....	4-53
4.5.6	Closure of Recruitment Cells.....	4-59
<b>4.6</b>	<b>Randomization and Enrollment.....</b>	<b>4-60</b>
4.6.1	Randomization Into CT.....	4-60
4.6.2	Enrollment Into OS.....	4-60
4.6.3	Randomization and Enrollment Procedures (Required).....	4-60
	HRT Randomization.....	4-61
	DM Randomization.....	4-61
	CaD Randomization.....	4-61
	OS Enrollment.....	4-62
	Remote Site Randomization.....	4-62
	DM Group Randomization.....	4-65
4.6.4	Back-up Enrollment and Randomization.....	4-65a
4.6.5	Blinding Considerations and Recommendations.....	4-73
	Definitive and Effective Unblinding.....	4-73
	Strategies for Maintaining Blinding.....	4-74

## Figures

4.1	Recommended Time Between Screening Visits.....	4-2
4.2	Estimated SV1 Activity Times.....	4-4
4.3	Overview of SV1 (Recommended).....	4-5
4.4	Estimated SV2 Activity Times.....	4-6
4.5	Overview of SV2 (Recommended).....	4-7
4.6	Estimated SV3 Activity Times.....	4-8
4.7	Overview of SV3 (Recommended).....	4-9
4.8	HRT Menopause Algorithm.....	4-46
4.9	DM & OS Menopause Algorithm.....	4-47
4.10	Nomogram for Body Mass Index.....	4-66
4.11	Initial Consent Script.....	4-67
4.12	HRT Consent Script.....	4-68
4.13	DM Consent Script.....	4-70
4.14	OS Consent Script.....	4-71
4.15	Suggested Script for Blinded Study Medication Dispensation.....	4-72
4.16	HRT Enrollment Pill Count To Pill Weight Conversion Chart.....	4-76

---

## SECTION 5: HORMONE REPLACEMENT TRIAL

---

<b>Introduction.....</b>	<b>5-1</b>
<b>5.1 HRT Eligibility Issues.....</b>	<b>5-2</b>
5.1.1 Informed Consent.....	5-2
5.1.2 Eligibility Based on Baseline Gynecologic Evaluations.....	5-2
Exclusions Based on Baseline Clinical Breast Exam Findings.....	5-2
Exclusions Based on Baseline Pelvic Exam Findings.....	5-2
Exclusions Based on Baseline Pap Smear.....	5-2
Exclusions Based on Baseline Endometrial Evaluation.....	5-3
Exclusions Based on Baseline Transvaginal Uterine Ultrasound.....	5-4
5.1.3 HRT "Washout" Period for Screenees Already on HRT.....	5-5

**5.2 Initiating the HRT Intervention .....5-6**

5.2.1 Step 1 – Introducing the HRT Intervention to the Participant ..... 5-6  
 Providing the *HRT Handbook* ..... 5-6  
 Reviewing the Importance of the HRT..... 5-6

5.2.2 Step 2 – Taking the HRT Study Pills ..... 5-6  
 Instructions for Taking Pills ..... 5-6  
 Using the Pill Organizer..... 5-6  
 Designing a Reminder System..... 5-6  
 Identifying and Building Skills ..... 5-7  
 Review..... 5-7

5.2.3 Step 3 – Understanding Symptoms ..... 5-7  
 Identify Fears and Beliefs ..... 5-7  
 Reviewing Possible Symptoms ..... 5-7  
 Review..... 5-7

5.2.4 Step 4 - Discussion of Routine Monitoring ..... 5-7  
 Reasons for Monitoring ..... 5-7  
 Self-Monitoring ..... 5-7  
 Symptom Monitoring..... 5-8  
 Clinical Monitoring ..... 5-8  
 Review..... 5-8

5.2.5 Randomization Visit ..... 5-8  
 Step 1 – Weighing Pills ..... 5-8  
 Step 2 – Monitoring Adherence and Symptoms ..... 5-8  
 Step 3 – Reviewing Key Points ..... 5-9

**5.3 Follow-Up Contacts with HRT Participants ..... 5-10**

5.3.1 Identifying Problems at Participant Contacts ..... 5-10

5.3.2 SERMs Handout..... 5-10

**5.4 Managing Symptoms..... 5-11**

5.4.1 Minor Symptoms ..... 5-11  
 Educate the Participant About Possible Symptoms ..... 5-11  
 Participants’ Reporting of Minor Symptoms ..... 5-11  
 Initial Management of Minor Symptoms ..... 5-11  
 Step-Down Dose Management for Refractory Symptoms..... 5-13

5.4.2 Management of Menopausal Symptoms..... 5-14

5.4.3 Management of Vaginal Bleeding..... 5-16  
 When to Biopsy ..... 5-17  
 Management According to Endometrial Histology ..... 5-18  
 Management According to TVUS Results..... 5-20  
 Additional Guidelines for Managing of Bleeding After First Year of HRT Study Pills ..... 5-20  
 Indefinite Use of Additional CEE 0.3 mg Daily ..... 5-21  
 Use of Cyclic CEE/MPA for HRT Participants ..... 5-21

**5.5 Problems That May Affect Continuation of Study Pills ..... 5-23**

5.5.1 Management of HRT After Hysterectomy for Non-Cancerous Condition ..... 5-23

5.5.2 Health Problems Requiring Serious Review..... 5-23

5.5.3 Health Problems That Require Temporary Discontinuation..... 5-24

5.5.4 Health Problems Requiring HRT Termination..... 5-24

5.5.5 Other Issues Requiring Discontinuation of HRT Study Pills ..... 5-25

5.5.6 Guidelines for Restarting a HRT Participant Who Discontinued Pills for 12 Months or More ..... 5-25

5.5.7 Guidelines for Restarting HRT Study Pills for a Participant Who Has Had a MI or Stroke..... 5-26

**5.6 Unblinding (Required) ..... 5-27**

**5.7 Follow-Up Endometrial Biopsies ..... 5-28**

5.7.1	Reading of Follow-Up Endometrial Biopsies .....	5-2
-------	---	-----

## Figures

5.1	Baseline Endometrial Aspiration Actions .....	5-5
5.2	Hormone Step-Down Management for Symptoms .....	5-15
5.3	Continued Menopausal Symptoms Management.....	5-16

---

## SECTION 6: DIETARY MODIFICATION (DM)

---

<b>Introduction .....</b>	<b>6-1</b>
---------------------------	------------

<b>6.1 Assessment of DM Eligibility Issues (Required).....</b>	<b>6-2</b>
--	------------

6.1.1	Food Frequency Questionnaire (Required).....	6-2
6.1.2	Low Fiber (Required) .....	6-2
6.1.3	BMI (Required).....	6-2
6.1.4	Number of Meals Prepared Away From Home (Required).....	6-2
6.1.5	Availability During Next Year (Required).....	6-3
6.1.6	DM Eligibility Checklist (Required).....	6-3
	Review DM Adherence Related Issues (Required) .....	6-3
	Review DM Design (Required) .....	6-6
	Review DM Expectations (Required) .....	6-6
	Review DM Randomization (Required).....	6-8

<b>6.2 Randomize DM Participant (Required) .....</b>	<b>6-9</b>
--	------------

<b>6.3 Handling Randomized DM Participants (Required).....</b>	<b>6-14</b>
--	-------------

6.3.1	Participants Assigned to the DM Comparison Group (Required).....	6-14
6.3.2	Participants Assigned to the DM Dietary Change Group (Required).....	6-14

<b>6.4 DM Intervention Goals and Design (Required).....</b>	<b>6-15</b>
---	-------------

6.4.1	Goals of DM Intervention (Required).....	6-15
6.4.2	Conceptual Design (Required).....	6-15
	Nutritional Themes (Required).....	6-15
	Behavior Themes (Required).....	6-15
6.4.3	Incorporation of Conceptual Design Into DM Intervention (Required).....	6-17
	Daily Fat Gram Goal (Required).....	6-17
	Integration of Nutritional and Behavioral Concepts (Required).....	6-17
	Sequencing of Behavioral Concepts (Required) .....	6-18

<b>6.5 Pre-Existing Diets and DM Intervention Participants (Required) .....</b>	<b>6-19</b>
---	-------------

6.5.1	Participants With Diabetes (Required) .....	6-19
-------	---	------

<b>6.6 Nutrition Policy Issues (Required) .....</b>	<b>6-20</b>
---	-------------

6.6.1	Calcium Supplements (Required).....	6-20
6.6.2	Donated Food Samples (Required).....	6-20

<b>6.7 Facility, Equipment, and Supply Requirements for DM Intervention (Required) .....</b>	<b>6-21</b>
--	-------------

6.7.1	Facilities (Required) .....	6-21
-------	-----------------------------	------

<b>6.8 DM Intervention Groups (Required) .....</b>	<b>6-22</b>
--	-------------

6.8.1	Description of DM Intervention Groups (Required).....	6-22
6.8.2	Forming DM Intervention Groups (Required) .....	6-22
	Scheduling Considerations.....	6-22



	Assignment of Group Nutritionist to DM Intervention Group (Required).....	6-23
	Handling DM Intervention Participants Waiting for a Group (Required).....	6-23
	Final Group Formation at the End of Recruitment.....	6-24
6.8.3	Maintaining Interest in Women Waiting for DM Intervention (Required).....	6-24
6.8.4	Combining DM Intervention Groups in First Year (Required).....	6-24a
<b>6.9</b>	<b>DM Intervention (Required).....</b>	<b>6-25</b>
6.9.1	Group Nutritionist and Participant Manuals (Required).....	6-25
	Group Nutritionist Manual (Required).....	6-25
	Participant Manual (Required).....	6-25
6.9.2	DM Intervention Schedule (Required).....	6-25
6.9.3	Individual Session (Required).....	6-25
6.9.4	Group Sessions (Required).....	6-27
	Content and Length (Required).....	6-27
	Delivery of Group Sessions (Required).....	6-27
	Format of Group Session (Required).....	6-28
6.9.5	Self-Monitoring (Required).....	6-29
	Aims of Self-Monitoring.....	6-29
	Self Monitoring Tools (Required).....	6-29
	Self-Monitoring Procedures (Required).....	6-30
	Self-Monitoring Issues.....	6-31
	Alternative Self-Monitoring Tools.....	6-31
<b>6.10</b>	<b>DM Intervention Participation (Required).....</b>	<b>6-32</b>
6.10.1	Travel and Group Participation (Required).....	6-32
6.10.2	Family and Friends Attendance at Group Sessions.....	6-32
6.10.3	Methods to Encourage Participation (Required).....	6-32
	Pre-Randomization Methods (Required).....	6-32
	Post-Randomization Methods.....	6-32
6.10.4	Monitoring Participation (Required).....	6-33
	Session Data Sheet ( <i>Form 63</i> ) (Required).....	6-33
	Individual Data Sheet ( <i>Form 64</i> ) (Required).....	6-33
	Home Activity Worksheets (Required).....	6-34
	Group Nutritionist Progress Notes (Required).....	6-34
6.10.5	Make-Up Activities for Women Who Miss Sessions (Required).....	6-34
	Procedures for Communicating With Women Who Miss Sessions (Required).....	6-34
	Description of Make-Up Plans for Women Who Miss Sessions (Required).....	6-35
	Data Collection for Women Who Miss Sessions (Required).....	6-36
6.10.6	Determining and Maintaining Levels of DM Intervention Participation (Required).....	6-36
	Participation Goals.....	6-36
	Definition of Non-Participation and Active Participation.....	6-37
6.10.7	Triage System for DM Intervention.....	6-37
	Participant Level of Effort.....	6-37
	Nutritionist Level of Effort.....	6-38
6.10.8	Interrupted DM Intervention Participation Procedures.....	6-38
	Awaiting Start-Up of DM Intervention.....	6-39
	Assessing the Situation for Interrupted DM Intervention Participation.....	6-39
	Developing and Implementing a Plan for Interrupted DM Intervention Participation.....	6-40
	Documenting and Tracking Interrupted DM Intervention Participation Plan and Contacts.....	6-40
	Reassessing the Interrupted DM Intervention Participation Plan.....	6-41
	Handling Participants Who Refuse Contact With the Group Nutritionist and Other CC Nutrition Staff.....	6-41
<b>6.11</b>	<b>Intensive Intervention Protocol (IIP) (Required).....</b>	<b>6-44</b>
6.11.1	IIP Sample (Who to Contact).....	6-44
6.11.2	Number, Type, and Frequency of Contacts.....	6-44
6.11.3	Framework of the Contact.....	6-46

6.11.4	Documenting IIP Contacts.....	6-51
6.11.5	Tracking IIP Contacts.....	6-53
6.11.6	IIP Sample Management.....	6-53
6.11.7	IIP Evaluation.....	6-55
<b>6.12</b>	<b>Maintenance of DM Intervention Participants (Required).....</b>	<b>6-57</b>
6.12.1	Group Sessions (Required).....	6-57
6.12.2	Newsletter.....	6-57
6.12.3	Peer-Led Groups.....	6-57
6.12.4	Social Activities for DM Intervention Participants.....	6-58
6.12.5	Make-Up Activities After First Year (Required).....	6-58
<b>6.13</b>	<b>Guidelines for Participants With Self-Reporting Scores Consistently &lt; 15 grams/day (Optional).....</b>	<b>6-59</b>
6.13.1	Identify Participants.....	6-59
6.13.2	Contacting Participants.....	6-59
6.13.3	Assessing Very Low-Fat Eating Patterns.....	6-59
6.13.4	Recording Contact(s).....	6-60
<b>6.14</b>	<b>Targeted Message Campaign (TMC) (Required).....</b>	<b>6-73</b>
6.14.1	TMC Slogan, Objectives, and Themes.....	6-73
6.14.2	TMC Sample (Who is Eligible).....	6-74
6.14.3	TMC Components.....	6-74
	Kickoff Newsletter – Sent CCC.....	6-74
	Mailing 1 (M1) – Sent by CCC.....	6-75
	TMC Phone Call – Conducted by CC Staff.....	6-75
	Mailing 2 (M2) – Sent by the CC.....	6-82
6.14.4	TMC Data Collection.....	6-88
6.14.5	TMC Management.....	6-89
6.14.6	WHILMA Resources for TMC Management.....	6-90
6.14.7	TMC Integration With Maintenance Sessions.....	6-90a
6.14.8	TMC Evaluation.....	6-90a
<b>6.15</b>	<b>Personalized Evaluation of Fat Intake (PEFI).....</b>	<b>6-91</b>
6.15.1	Behavioral Foundation.....	6-91
	Principles.....	6-92
	Skills and Strategies.....	6-93
6.15.2	PEFI Components.....	6-93
	PEFI Self-Assessment Questionnaire (PEFI-Q).....	6-93
	Design and Content.....	6-93
	Quality Control.....	6-96
	Defaults for Missing Information.....	6-96
	Errors that Prevent Analysis.....	6-97
	Tailored Feedback (PEFI-F).....	6-97
6.15.3	PEFI Implementation.....	6-102
	Summer 2002 (8SU) Session.....	6-102
	Fall 2002 (9F) Session.....	6-102
6.15.4	PEFI Management.....	6-105
	Lead Nutritionist Responsibilities.....	6-105
	Intervention Issues.....	6-106
	Managing Participants with ‘Stop’ DM Intervention Status.....	6-106
	Managing Participants with a Negotiated Fat Gram Goal.....	6-107
	Managing Participants Who Report <15 Grams of Fat.....	6-107
	Managing Participants Who Attend 9F, but Do Not Have PEFI-F.....	6-108
	Managing Participants Who Complete 8SU and/or 9F by Mail or Phone.....	6-108
	Managing Participants Who Are Guests from a Different Clinical Center.....	6-109

	Managing Participants with Adherence and Retention Challenges .....	6-110
6.15.5	PEFI Data Processing .....	6-111
	Collection, Review, and Processing of the PEFI-Q .....	6-112
	Generating Tailored Feedback (PEFI-F).....	6-113
6.15.6	WHILMA Resources for PEFI Tracking.....	6-114
	PEFI Tracking Screen.....	6-114
	PEFI Contact 1 Tracking Report.....	6-116
6.15.7	Scientific Issues.....	6-118
<b>6.16</b>	<b>Personalized Evaluation of Fat Intake 2003 (PEFI 2003).....</b>	<b>6-120</b>
6.16.1	PEFI 2003 Components .....	6-120
	PEFI-Q Cover Letter/Instructions .....	6-120
	PEFI-Q (ver. 2).....	6-120
	PEFI-F.....	6-121
	Guide for Your PEFI Packet.....	6-121
6.16.2	PEFI 2003 Implementation .....	6-121
	Central (CCC) Administration of PEFI 2003.....	6-121
	Local (CC) Administration of PEFI 2003 .....	6-122
6.16.3	WHILMA Resources for PEFI 2003 .....	6-123
	PEFI 2003 Mailing Selection Screen .....	6-123
	PEFI 2003 Mailing Selection Report .....	6-123
	PEFI 2003 Tracking Screen.....	6-123
	PEFI 2003 Tracking Report.....	6-124
6.16.4	PEFI 2003 Intervention Summary .....	6-124
<b>6.17</b>	<b>Closure of the DM Intervention Sessions .....</b>	<b>6-125</b>
6.17.1	Year 10 Sessions Overview.....	6-125
6.17.2	Final DM Intervention Session.....	6-125
6.17.3	Activities for Women Who Miss the Summer 2004 (10SU) Session.....	6-126

## Figures

6.1a.	DM Eligibility Checklist.....	6-10
6.1b	DM Eligibility Checklist With Questions .....	6-11
6.2	Interrupted DM Intervention Participation Flow.....	6-42
6.3	Interrupted DM Intervention Participation Worksheet.....	6-43
6.4	Scheduling IIP Contact #1 – Sample Script.....	6-45
6.5	IIP Simple Roadmap .....	6-47
6.6	WHI IIP Detailed Roadmap.....	6-48
6.7	IIP Progress Notes (Example).....	6-52
6.8	Outline for Group Nutritionist Areas to Review When Assessing a Very Low-Fat Eating Pattern .....	6-61
6.9	Group Nutritionist Assessment Worksheet.....	6-63
6.10	Themes – Overview .....	6-73
6.11	Mailing 1 – Cards by Theme.....	6-75
6.12	TMC Phone Call Overview .....	6-77
6.13	TMC Phone Call Guide .....	6-78
6.14	Getting Back on Track .....	6-81
6.15	Mailing 2 Activities by Readiness & Theme .....	6-83
6.16	PEFI Intervention .....	6-91
6.17	Template: Equivalency Help Sheet for Local Foods .....	6-96
6.18	Sample PEFI-Tracking Sheet.....	6-116
6.19	Year 10 Sessions Overview.....	6-127

## Tables

6.1a	Number of Fat Scans to Assign Dependent on Placement of Individual Session (4-Week Interval).....	6-26
------	---	------

6.1b	Number of Fat Scans to Assign Dependent on Placement of Individual Session (6-Week Interval).....	6-27
6.2	Triage System for DM Intervention .....	6-38
6.3	Summary of DM Intervention Sessions.....	6-69
6.4	Sample DM Intervention Group Tracking Sheet .....	6-72
6.5	Components and Timeline for WHI DM Targeted Message Campaign.....	6-74
6.6	Types of Adjustment Questions Used in the PEFI-Q .....	6-94
6.7	Summary of PEFI-F Pages .....	6-100
6.8	Summer 2002 (8SU) Session.....	6-103
6.9	Fall 2002 (9F) Session .....	6-104
6.10	Suggestions for PEFI Implementation in Response to A&R Survey .....	6-111

---

## SECTION 7: CALCIUM AND VITAMIN D INTERVENTION

---

<b>Introduction .....</b>	<b>7-1</b>
<b>7.1 Recruitment and Randomization (Required).....</b>	<b>7-2</b>
7.1.1 Preparation for the First Annual Visit (Recommended).....	7-2
7.1.2 Activities During the First Annual Visit (Required) .....	7-2
7.1.3 Eligibility (Required) 7-2	
7.1.4 CaD Information and Consent (Required).....	7-3
CaD Study Pill Taste/Swallow Test Procedure .....	7-3
Informed Consent (Required).....	7-4
7.1.5 Randomization Activities (Required) .....	7-6
7.1.6 Implementing the CaD Intervention After Randomization.....	7-6

**This page left blank intentionally.**

7.1.7	Exit Interviews (Recommended).....	7-8
<b>7.2</b>	<b>Follow-Up Contacts with CaD Participants .....</b>	<b>7-9</b>
7.2.1	Forms Review (Required) 7-9	
7.2.2	Identifying Problems at Participant Contacts .....	7-9
	Switch of Formulations .....	7-9
	Intensive Adherence Plan (Required).....	7-10
7.2.3	Dispense Study Pills (Required) .....	7-10
7.2.4	Osteoporosis Handout .....	7-10
<b>7.3</b>	<b>Adverse Effects.....</b>	<b>7-12</b>
7.3.1	Monitoring for Adverse Effects (Required).....	7-12
7.3.2	Minor Adverse Effects (Required) .....	7-12
	Management of Minor Symptoms .....	7-12
7.3.3	Major Adverse Effects and Events (Required).....	7-13
	Management of Major Adverse Effects and Events .....	7-13
7.3.4	Unblinding (Required).....	7-13
<b>Figures</b>		
7.1	CaD Consent Script.....	7-15
7.2	New CaD Formulation Scripts for Participants Randomized to CaD .....	7-16
<b>Table</b>		
7.1	Step-Down Procedures for Managing Adherence Problems or Minor Adverse Effects .....	7-11

---

## SECTION 8: OBSERVATIONAL STUDY

---

<b>Introduction .....</b>	<b>8-1</b>	
<b>8.1 Eligibility for the OS.....</b>	<b>8-2</b>	
<b>8.2 Inviting Women Into the OS .....</b>	<b>8-3</b>	
8.2.1 Identifying OS Participants .....	8-3	
8.2.2 Determining Eligibility for the OS .....	8-3	
8.2.3 Informed Consent for OS .....	8-3	
8.2.4 Entry Into OS Outside a CC Visit .....	8-4	
<b>8.3 Baseline Procedures for OS Participants .....</b>	<b>8-5</b>	
8.3.1 Questionnaires and Procedures Administered at a CC Visit .....	8-5	
8.3.2 Self-Administered Questionnaires .....	8-6	
8.3.3 Procedures for Questionnaires Not Returned to CC.....	8-7	
8.3.4 Maximum Time for Completion of Baseline Data.....	8-7	
8.3.5 Quality Assurance Procedures .....	8-7	
8.3.6 Ending the OS Baseline Visit .....	8-8	
	Annual Newsletters .....	8-8
	Yearly Update Questionnaires .....	8-8
	Future CC Visits.....	8-8
	Arranging Follow-Up for OS Participants .....	8-9
8.3.7 Enrolling Women in the OS .....	8-9	
8.3.8 Reporting Abnormal Findings.....	8-9	
8.3.9 Baseline Procedures on Participants Who Have Completed Part of the Screening Process		
	Before September 1994 .....	8-9
<b>8.4 OS Measurement Precision Study - OS-MPS .....</b>	<b>8-11</b>	

8.4.1	Participants.....	8-11
8.4.2	Forms.....	8-11
8.4.3	Procedures.....	8-13
<b>8.5</b>	<b>Follow-Up Procedures for OS Participants .....</b>	<b>8-15</b>
8.5.1	Annual Newsletter.....	8-15
8.5.2	Annual Mail Contact .....	8-15
8.5.3	Follow-Up of Non-Respondents.....	8-15
8.5.4	Three Year Visit to CC.....	8-15

## Figures

8.1	Telephone Script for Enrolling OS Women by Mail (For Those Who Have Completed OS Screening Tasks That Require a CC Visit).....	8-16
8.2	Telephone Script for Follow-Up Reminder to OS Women (For Those Who Have Not Returned Their Questionnaires by Three Weeks Post-Mailing).....	8-18
8.3	Telephone Script for Contacting OS Women to Participate in OS-Measurement Precision Study.....	8-20
8.4	OS Measurement Precision Study Cover Letter.....	8-21

---

## SECTION 9: CLINICAL MEASUREMENTS

---

<b>Introduction .....</b>	<b>9-1</b>
<b>9.1 Resting Pulse (Required).....</b>	<b>9-2</b>
9.1.1 Training and Certification .....	9-2
9.1.2 Performing the Measurement .....	9-2
9.1.3 Alert Values for Resting Pulse .....	9-2
<b>9.2 Blood Pressure (Required).....</b>	<b>9-3</b>
9.2.1 Training and Certification .....	9-3
9.2.2 Blood Pressure Procedures.....	9-3
Blinding.....	9-3
Arm Circumference Measurement .....	9-3
Rest Period .....	9-4
Application of the Cuff.....	9-4
Determining the Maximal Inflation Level.....	9-5
Performing the Measurement .....	9-5
9.2.3 Criteria for Systolic and Diastolic Blood Pressure .....	9-5
9.2.4 Guidelines for Blood Pressure Readings .....	9-6
9.2.5 Maintenance of Sphygmomanometer .....	9-6
9.2.6 Alert Values.....	9-6
<b>9.3 Height (Required).....</b>	<b>9-8</b>
9.3.1 Training and Certification .....	9-8
9.3.2 Performing the Measurement .....	9-8
9.3.3 Maintenance of Wall-Mounted Stadiometer .....	9-8
9.3.4 Reliability Testing of Portable Stadiometer.....	9-9a
<b>9.4 Weight (Required).....</b>	<b>9-11</b>
9.4.1 Training and Certification .....	9-11
9.4.2 Performing the Measurement .....	9-11
9.4.3 Maintenance of Scale .....	9-11
9.4.4 Calibration Check.....	9-11
9.4.5 Portable Scales.....	9-11





<b>9.5</b>	<b>Waist and Hip Circumference (Required)</b> .....	<b>9-12</b>
9.5.1	Training and Certification .....	9-12
9.5.2	Performing the Measurement (Waist Circumference).....	9-12
9.5.3	Performing the Measurement (Hip Circumference).....	9-12
9.5.4	Maintenance of Measurement Tool.....	9-12
<b>9.6</b>	<b>Functional Measurements (Subsample Only) Status</b> .....	<b>9-13</b>
9.6.1	Functional Status Measurement Procedures for Older Women .....	9-13
	Footwear.....	9-13
	Physical Limitations and Safety Precautions .....	9-13
	Refused/Unable (Required) .....	9-13
	Falls .....	9-13
	Improving Data Quality .....	9-14
9.6.2	Training and Certification .....	9-14
9.6.3	Grip Strength (Required) .....	9-14
	Grip Strength Procedure.....	9-14
	Maintenance of Hand Grip Dynamometer.....	9-15
9.6.4	Chair Stand (Required) .....	9-16
	Chair Stand Procedure.....	9-16
9.6.5	Timed Walk (Required).....	9-17
	Gait Course.....	9-17
	Timed Walk Procedure .....	9-17
<b>9.7</b>	<b>Clinical Breast Exam (Required)</b> .....	<b>9-18</b>
9.7.1	Training and Certification .....	9-18
9.7.2	Performing the CBE.....	9-18
<b>9.8</b>	<b>Breast Self-Exam Instruction (Required)</b> .....	<b>9-19</b>
9.8.1	Training and Certification .....	9-19
9.8.2	Performing Breast Self-Exam (BSE) Instruction .....	9-19
<b>9.9</b>	<b>Pelvic Exam and Pap Smear</b> .....	<b>9-20</b>
9.9.1	Training and Certification .....	9-20
9.9.2	Performing the Pelvic Exam and Obtaining the Pap Smear.....	9-20
9.9.3	Pelvic Exam and Pap Smear Findings .....	9-21
<b>9.10</b>	<b>Endometrial Aspiration</b> .....	<b>9-22</b>
9.10.1	Training and Certification .....	9-22
9.10.2	Antibiotic Prophylaxis .....	9-22
9.10.3	Performing the Endometrial Aspiration.....	9-22
9.10.4	Performing Transvaginal Uterine Ultrasound .....	9-23
<b>9.11</b>	<b>Cognitive Assessment (Required)</b> .....	<b>9-24</b>
9.11.1	Overview.....	9-24
9.11.2	Training and Certification .....	9-24
9.11.3	Prepare for the Interview.....	9-25
9.11.4	Conducting the Cognitive Assessment Interview.....	9-25

---

## SECTION 10: DIETARY ASSESSMENT

---

<b>Introduction</b> .....	<b>10-1</b>
---------------------------	-------------

<b>10.1</b>	<b>The Four-Day Food Record (4DFR) (Required)</b> .....	<b>10-3</b>
10.1.1	Activities at SV2.....	10-4
10.1.2	Activities at SV3.....	10-4
10.1.3	Follow-Up Visit Record Completion.....	10-4
10.1.4	Baseline Food Record Documentation.....	10-5
10.1.5	Follow-Up Visit Food Record Documentation.....	10-5
10.1.6	Common Problems and Solutions.....	10-6
	A Participant Does Not Complete Her Baseline 4DFR.....	10-6
	A Participant Fails to Return Her Follow-Up 4DFR.....	10-6
	A Baseline 4DFR is Unacceptable.....	10-6
	A Participant is Sick During the Record Keeping Period.....	10-6
	A Participant Does Not Record Alternate Days of Intake.....	10-6
10.1.7	4DFR Processing.....	10-6
	CC Procedures for Processing Documented 4DFRs.....	10-6
	CCC Procedures for Processing Documented 4DFRs.....	10-7
	CCC Review Procedures for Documented 4DFRs Received From the CCs.....	10-7
	Lead Nutritionist Procedures for Unacceptable Documented 4DFRs.....	10-7
10.1.8	Quality Assurance of 4DFRs (Required).....	10-8
	CC Documentation and Peer Review Procedures for Documented 4DFRs.....	10-8
	4DFR Documentation Performance Standards.....	10-8
	Dietary Assessment Quality Assurance Reports.....	10-8
	Quality Assurance of 4DFR Data Entry (Required).....	10-9
<b>10.2</b>	<b>The FFQ (Required)</b> .....	<b>10-10</b>
10.2.1	Distributing and Completing the FFQ.....	10-10
	Baseline (Screening) FFQ.....	10-11
10.2.2	Processing the FFQ.....	10-11
10.2.3	Reviewing and Editing the FFQ.....	10-11
	Cursory Review.....	10-11
	Pre-Scan Edit.....	10-11
	Guidelines for Interviewing Participants.....	10-12
	Non-Leading Questions.....	10-12
10.2.4	Computer Scanning of the FFQ.....	10-12
10.2.5	FFQ Error Report.....	10-13
	Post-Scan Edit.....	10-13
10.2.6	FFQ Analysis Results.....	10-14
10.2.7	FFQ Storage.....	10-14
	Follow-Up FFQs.....	10-14
<b>10.3</b>	<b>The 24HR (Required)</b> .....	<b>10-15</b>
10.3.1	CC Procedures for the DM 24HR Cohort.....	10-15
10.3.2	CCC Procedures for 24HR.....	10-15

**Figures**

10.1	WHI 4DFR Documentation Checklist.....	10-16
10.2	Guidelines for Documenting the Fat Added Columns of the 4DFR.....	10-22
10.3	4DFR Screening Checklist.....	10-25
10.4	Sample of FFQ Error Report.....	10-26

---

**SECTION 11: BLOOD AND URINE COLLECTION, PROCESSING, AND SHIPMENT**

---

<b>Introduction</b> .....	<b>11-1</b>
---------------------------	-------------

**11.1 General Guidelines ..... 11-2**

11.1.1 Safety Procedures - Precautions for Handling Blood ..... 11-2

11.1.2 Training and Certification (Required)..... 11-3

11.1.3 Facilities ..... 11-4

11.1.4 Equipment and Supplies (Required)..... 11-4

**11.2 Blood Collection..... 11-5**

11.2.1 Blood Sample Labels (Required)..... 11-5

11.2.2 Identification of Participants Requiring Blood Collection ..... 11-7

Routine Visits ..... 11-7

Quality Assurance (QA) Samples..... 11-7

11.2.3 Volume of Blood to Collect (Required) ..... 11-7

Blood Sample for the Local Lab (Required)..... 11-8

Routine Blood Sample for the Serum Repository (Required) ..... 11-8

11.2.4 Preparation for Blood Collection..... 11-8

General Instructions for Participants Before Blood Draws (Required) ..... 11-8

Directions for Staff When Participants Do Not Follow Instructions (Required)..... 11-9

Preparation Before the Visit ..... 11-9

Preparation at the Visit (Required)..... 11-10

Participant Preparation (Required)..... 11-10

Handling Participants Who Are Extremely Apprehensive About Having Blood Drawn ..... 11-11

11.2.5 Venipuncture..... 11-12

Wash Hands and Put on Gloves ..... 11-12

Assemble the Vacutainer Holder ..... 11-12

Identify Venipuncture Site ..... 11-12

Perform Venipuncture ..... 11-13

Bandage the Arm..... 11-13

11.2.6 Blood Collection Problems..... 11-14

Special Consideration for Drawing Blood in the Elderly ..... 11-14

Difficult-to-Identify-Venipuncture Sites ..... 11-14

Difficult Venipuncture ..... 11-14

Fainting ..... 11-15

Deficient Serum and Plasma Samples ..... 11-16

11.2.7 Summary of Blood Collection Procedure ..... 11-17

**11.3 Blood Processing..... 11-18**

11.3.1 Timelimits and Sample Handling ..... 11-18

CBC..... 11-18

11.3.2 Operating the Refrigerated Centrifuge ..... 11-20

11.3.3 Processing Samples ..... 11-22

Preparation of Blood Cryovials (Required) ..... 11-23

11.3.4 Tracking Specimens for Local Lab..... 11-27

11.3.5 Freezing and Storing Blood Cryovials (Required)..... 11-27

Equipment Quality Assurance (Required)..... 11-28

11.3.6 Summary of Blood Processing Procedures ..... 11-28

**11.4 Blood Storage and Shipping ..... 11-30**

11.4.1 Shipping Schedule (Required)..... 11-30

Mailing Instructions (Required)..... 11-30

Mailing Instructions for Visiting Participants (Required)..... 11-30

11.4.2 Packaging Instructions (Required)..... 11-32

11.4.3 Receipt of Frozen Specimen Shipment at McKesson BioServices ..... 11-37

11.4.4 Summary of Blood Sample Shipping Procedures ..... 11-37

**11.5 Urine Collection..... 11-38**

11.5.1 Schedule of Urine Collection ..... 11-38

11.5.2 Urine Sample Labels ..... 11-38

11.5.3 Preparation Before the Visit ..... 11-38

11.5.4 At the Visit ..... 11-39

**11.6 Urine Processing..... 11-40**

**11.7 Freezing, Storing, and Shipping Urine Samples ..... 11-40**

**Figures**

11.1 Blood Sample Labels ..... 11-6

11.2 Blood Collection and Aliquot Schedule ..... 11-7

11.3 Guidelines for Blood Processing ..... 11-19

11.4 Nomogram for Calculating RCF..... 11-21

11.5 Sample Blood Processing Rack Set-Up..... 11-23

11.6 Processing Blood Samples..... 11-26

11.7 Specimen Storage Box..... 11-29

11.7A Notification of WHI Shipment..... 11-31

11.8 Frozen Specimen Shipping Labels ..... 11-35

11.9 Federal Express Airbill for Frozen Specimens ..... 11-36

11.10 Urine Sample Labels..... 11-38

11.11 WHI Urine Home Collection..... 11-39

11.12 Instructions for Home Urine Collection ..... 11-39

---

**SECTION 12: MAMMOGRAPHY**

---

**Introduction ..... 12-1**

**12.1 Timing of Mammogram..... 12-2**

**12.2 Scheduling Mammograms ..... 12-3**

12.2.1 Baseline Mammogram ..... 12-3

12.2.2 Follow-Up Mammograms ..... 12-3

    Annual Visit Mammograms ..... 12-3

    Annual Visit Mammograms Following a Mammogram Requiring Follow-Up in Less Than a Year..... 12-3

12.3 Requesting and Receiving Mammogram Results ..... 12-4

12.3.1 Receiving Mammograms at Unscheduled Times ..... 12-4

    Lay Mammogram Reports ..... 12-4

**12.4 Actions Based on Baseline Mammogram Reports ..... 12-5**

12.4.1 Negative or Benign Mammogram Findings ..... 12-5

12.4.2 Probable Benign Findings ..... 12-5

12.4.3 Suspicious or Highly Suggestive of Malignancy Findings ..... 12-7

12.4.4 Mammograms Requiring Short-Term Follow-Up..... 12-7

**12.5 Actions Based on Mammogram Reports for Randomized Women..... 12-8**

12.5.1 Negative or Benign Findings ..... 12-8

12.5.2 Probable Benign Findings ..... 12-8

12.5.3 Suspicious or Highly Suggestive of Malignancy Findings ..... 12-8

**Tables**

12.1 Eligibility Based on Mammogram Results ..... 12-6

**SECTION 13: ECG PROCEDURES**

**Introduction ..... 13-1**

**13.1 General Requirements and Set-Up..... 13-2**

13.1.1 Storing Supplies ..... 13-2

13.1.2 MACPC Description ..... 13-2

MACPC Keyboard Description ..... 13-2

MACPC Set-Up ..... 13-5

Date and Time Set-Up..... 13-5

Phone Set-Up ..... 13-6

Miscellaneous Set-Up ..... 13-6

**13.2 Preparing for ECG Recording ..... 13-10**

13.2.1 Limb Lead Electrode Placement..... 13-10

13.2.2 Locating Chest Electrodes ..... 13-13

Locating Chest Electrodes in Large Chested Women ..... 13-14

13.2.3 Skin Preparation for Chest Electrodes..... 13-19

13.2.4 Attachment of Electrode Cables ..... 13-19

13.2.5 ECG Preparation Summary ..... 13-22

13.2.6 Registering Participant in the ECG Log..... 13-23

13.2.7 Entering Participant ID ..... 13-23

**13.3 Recording the 12-Lead ECG..... 13-25**

13.3.1 Error Messages..... 13-25

13.3.2 Quality Check After Recording ..... 13-25

13.3.3 Post-Examination Procedures ..... 13-32

13.3.4 Definition of Alerts ..... 13-32

**13.4 Transmitting ECGs ..... 13-40**

13.4.1 Directory ..... 13-40

13.4.2 Deleting an ECG and Editing an Invalid ID Number ..... 13-41

13.4.3 Transmitting an ECG..... 13-45

13.4.4 Procedures at the End of Each Working Day ..... 13-45

**13.5 ECG Quality Assurance Procedures ..... 13-46**

13.5.1 ECG Quality Assurance at the Clinical Centers ..... 13-46

13.5.2 Certification in ECG Procedures ..... 13-46

13.5.3 Quality Assurance Summary ..... 13-46

**Figures**

13.1 Liquid Crystal Display and Keyboard Description ..... 13-4

13.2 Placement of Limb Leads ..... 13-12

13.3 Anatomy of the Sternum..... 13-15

13.4 Anatomic Structure of the Thorax..... 13-16

13.5 Location of Chest Electrodes ..... 13-17

13.6 Heart Square..... 13-18

13.7 Acquisition Module 3 (AM3)..... 13-20

13.8 Acquisition Module 4 (AM4)..... 13-21

13.9 Excessive Baseline Drift ..... 13-27

13.10 Excessive Muscle Noise..... 13-28

13.11 Motion Artifacts or Loose Electrode Contact ..... 13-29

13.12 Lead Reversal, V1 - V3..... 13-30

13.13 Lead Reversal, LA-RA..... 13-31

13.14	Atrial Fibrillation.....	13-34
13.15	Sinus Bradycardia .....	13-35
13.16	3° AV Block.....	13-36
13.17	Sinus Tachycardia $\geq$ 130 bpm.....	13-37
13.18	Sinus Tachycardia $\geq$ 140 bpm.....	13-38
13.19	Ventricular Pre-Excitation Wolf-Parkinson-White (WPW) or Mobitz Type II AV Block.....	13-39

## Tables

13.1	ECG Preparation Summary .....	13-22
13.2	Checklist for Recording ECGs .....	13-48
13.3	Checklist for Processing ECGs .....	13-49

---

## SECTION 14: BONE DENSITOMETRY

---

- Moved to Volume 6 - DXA Quality Assurance.

---

## SECTION 15: MEDICATIONS (STUDY PILLS)

---

<b>Introduction .....</b>	<b>15-1</b>
<b>15.1 Medications (Study Pills).....</b>	<b>15-2</b>
15.1.1 HRT Component.....	15-2
Enrollment Pills .....	15-2
HRT for Randomized Participants.....	15-2
Open Label Study Pills .....	15-3
15.1.2 CaD Component .....	15-3
15.1.3 Child-Resistant Caps (Required).....	15-3a
<b>15.2 Study Pill Storage Area (Required).....</b>	<b>15-5</b>
15.2.1 Storage Area Specifications .....	15-5
15.2.2 Storage Area Organization.....	15-5
15.2.3 Storage Area Work Space.....	15-5
<b>15.3 Study Pill Inventory Maintenance .....</b>	<b>15-6</b>
15.3.1 Minimum Inventory (Required).....	15-6
15.3.2 Request Study Pills from McKesson (Required).....	15-6
15.3.3 Receiving Study Pills (Required).....	15-8
15.3.4 Returning Study Pills to McKesson (Required).....	15-8
Returning HRT Study Pills.....	15-8
Returning CaD Study Pills .....	15-9
Returning Discarded CaD Pills to McKesson.....	15-9
<b>15.4 Study Pill Dispensing (Required).....</b>	<b>15-10</b>
15.4.1 Selecting and Dispensing Enrollment HRT Bottles at Screening Visit 2 (SV2) (Required).....	15-10
Preparation (Required).....	15-10
Selecting and Dispensing at SV2 (Required) .....	15-10
Repeat HRT Enrollment Period.....	15-11
Selecting Enrollment Pills When There are Computer Problems (Required).....	15-11
15.4.2 Selecting and Dispensing HRT Bottles at Screening Visit 3 (SV3) (Required).....	15-11

Preparation (Required)..... 15-11  
 Selecting and Dispensing at SV3 (Required) ..... 15-11  
 15.4.3 Selecting and Dispensing HRT Study Pill Bottles at Semi-Annual and Annual Visits (Required) ..... 15-12  
     Preparation ..... 15-12  
     Selecting and Dispensing at Follow-Up Contacts (Required)..... 15-12  
 15.4.4 Selecting and Dispensing Open Label HRT Study Pills (Required)..... 15-12  
 15.4.5 Selecting and Dispensing CaD Study Pills (Required)..... 15-13  
 15.4.6 Switching CaD Formulations ..... 15-13  
 15.4.7 Selecting and Dispensing Study Pills for Remote Site Locations (Required)..... 15-14  
     Select the Study Pills Before the Clinic Visit ..... 15-14  
     Select the Study Pills After the Clinic Visit ..... 15-14a  
     Strategies for Selecting and Dispensing Study Pills for Remote Site Locations ..... 15-14a  
**15.5 Selecting and Dispensing Problems (HRT/CaD) (Required)..... 15-15**  
 15.5.1 Abnormal Lab Results While on HRT Enrollment Pills ..... 15-15  
 15.5.2 Bottle is Lost or Damaged Before You Dispense It (Required)..... 15-15  
 15.5.3 Participant Has a Lost or Damaged Bottle (Required)..... 15-15  
 15.5.4 Participant's Supply Runs Out (Required)..... 15-16  
     HRT Enrollment Pills ..... 15-16  
     Study Pills (HRT, CaD)..... 15-16  
 15.5.5 No Bottles Available (Required)..... 15-16  
 15.5.6 Participant Drops Out (Required) ..... 15-17  
 15.5.7 Transferred Participants (Required) ..... 15-17  
 15.5.8 Reactivated Participants (Required)..... 15-17  
**15.6 Study Pill Adherence Monitoring (Required)..... 15-18**  
 15.6.1 Purpose ..... 15-18  
 15.6.2 Adherence Assessment..... 15-18  
     Approach to Participant (Required) ..... 15-18  
     Weighing Procedures (Required) ..... 15-19  
     HRT Enrollment Adherence (Required)..... 15-23  
     HRT and CaD Semi-Annual and Annual Follow-Up Contacts (Required)..... 15-23  
     HRT and CaD Bottles Returned by Mail (Required)..... 15-24  
     HRT and CaD Bottles Not Returned (Required)..... 15-25  
**15.7 Study Pill Problems ..... 15-27**  
 15.7.1 Overdose ..... 15-27  
     Treatment..... 15-27  
     Unblinding..... 15-27  
     Managing Overdose Calls ..... 15-27  
 15.7.2 Serious Adverse Experiences (SAEs) ..... 15-28  
**15.8 Managing Adherence..... 15-29**  
 15.8.1 Intensive Adherence Program (Required) ..... 15-29

**Figures**

15.1 Sample HRT Label..... 15-2  
 15.2a Sample CaD Labels a. Chewable CaD Tablets ..... 15-3a  
 15.2b Swallowable CaD Pills..... 15-3a  
 15.3 CaD Disposal Log Example ..... 15-9a  
 15.4 Study Pill Weighing Procedure ..... 15-22  
 15.5 Study Pill Adherence Assessment (For Follow-Up Contact)..... 15-26

**Tables**

15.1	List of Discrepancies Between Drug Inventory Report ( <i>WHIP0032</i> ) and Actual Inventory, Possible Causes, and Actions to Take .....	15-7
15.2	WHI Placebo Ingredients (PERT Placebo).....	15-30
15.3	WHI Placebo Ingredients (ERT Placebo).....	15-31
15.4	WHI Chewable CaD Ingredients.....	15-31
15.5	WHI Swallowable CaD Ingredients.....	15-32

---

## SECTION 16: FOLLOW-UP CONTACTS

---

<b>Introduction</b> .....	<b>16-1</b>
<b>16.1 Early Adherence and Safety Telephone Contact (HRT and CaD) (Required)</b> .....	<b>16-2</b>
16.1.1 Preparation for the Telephone Contact.....	16-2
16.1.2 Conducting the Telephone Contact.....	16-2
Introduction and Personal Information Update (Required).....	16-2
Safety Interview (Required).....	16-3
Concluding the Phone Call.....	16-3a
<b>16.2 Semi-Annual Contact (CT only) (Required)</b> .....	<b>16-4</b>
16.2.1 Preparation for a Semi-Annual Visit .....	16-4
Two Weeks Before a Semi-Annual Visit.....	16-4
Two days Before a Semi-Annual Visit .....	16-5
16.2.2 Conducting the Semi-Annual Visit (Required) .....	16-5
Reception.....	16-5
Semi-Annual Visit Procedures (Required).....	16-6
16.2.3 Exit Interview .....	16-7
<b>16.3 Annual (CT) and Third-Year (OS) Visit (Required)</b> .....	<b>16-8</b>
16.3.1 Preparation for the Annual (CT) and Third-Year (OS) Visit.....	16-8
Two Months Before the Annual Visit (CT).....	16-8
Two Weeks Before the Annual (CT) and Third-Year (OS) Visit.....	16-9
A Few Days Before the Annual (CT) and Third-Year (OS) Visit .....	16-10
Activities on the Morning of the Annual (CT) and Third-Year (OS) Visit.....	16-10
16.3.2 Conducting the Annual (CT) and Third-Year (OS) Visit (Required) .....	16-11
CaD Review at First Annual Visit (Required).....	16-11
Reception.....	16-11
Annual (CT) and Third-Year (OS) Visit Procedures (Required).....	16-12
Exit Interview .....	16-15
16.3.3 Post-Visit Review (Required).....	16-15
Blood Test Results (Required).....	16-16
Pelvic Exam and Pap Smear Results (HRT) (Required).....	16-16
Endometrial Aspiration Results (HRT) (Required).....	16-16
Mammogram Report Results (Required).....	16-16
Bone Density Scan (Bone Density Sites Only) (Required).....	16-16
Personal Information Update ( <i>WHIP 0441</i> ) .....	16-16
<b>16.4 Follow-Up Contact Problems for Annual (CT) and Third-Year (OS) Visits</b> .....	<b>16-17</b>
16.4.1 Missed Follow-Up Contacts.....	16-17
Strategies for Avoiding Missed Contacts.....	16-17
Strategies for Managing Missed Contacts (Required).....	16-18
16.4.2 Minimum Procedures Required for a CT Participant to Remain on Intervention (Required).....	16-18c
Hormone Replacement Therapy (Required).....	16-18c
Calcium/Vitamin D (Required) .....	16-19



---

	Dietary Modification .....	16-19a
16.4.3	Guidelines for Restarting Participant Who Discontinued Pills for 12 Months or More..... Restarting HRT.....	16-19a 16-19a
<b>16.5</b>	<b>OS Annual Mail Contact and Follow-Up of Non-Responders .....</b>	<b>16-20</b>
16.5.1	CCC Responsibilities for Annual OS Follow-Up .....	16-20
	Mailing of Annual OS Questionnaire Follow-Up Packet 1 (Contact 1).....	16-20
	Mailing of the Thank You/Reminder Postcard (Contact 2 – Discontinued in May 1997).....	16-21

	Second Mailing of Entire Follow-Up Packet (Contact 3).....	16-21
	Third Mailing of Entire Follow-Up Packet (Contact 4).....	16-21
16.5.2	CC Responsibilities During Annual OS Follow-Up Mailings (Required).....	16-21
	Processing Returned Packets (Contacts 1-4) (Required).....	16-21
	Making Address Corrections (Required).....	16-22
	Running Monthly OS Follow-Up Reports From WHILMA (Required).....	16-23
16.5.3	CC Data Collection for Non-Respondents to OS Mailings (Required).....	16-24
	Telephone Contact to Ascertain Correct Address and to Collect Medical History Update (Contact 5) (Required).....	16-24
	Mail/Phone Contact to Trace Participant and/or Collect Medical History Update from Proxy (Contact 6) (Required).....	16-25
<b>16.6</b>	<b>Follow-Up by Proxy (Required).....</b>	<b>16-26</b>
16.6.1	Designating a Proxy (Required).....	16-26
	For CT Participants Attending Clinic Visits.....	16-26
	For OS Participants Attending AV3.....	16-27
	For OS Participants Beyond AV3.....	16-27
	For Participants Who Do Not Have a Designated Proxy.....	16-27
16.6.2	Proxy Follow-Up Contact Procedures (Required).....	16-27
	Proxy Follow-Up Procedures for CT Participants (Required).....	16-27a
	Proxy Follow-Up Procedures for OS Participants (Required).....	16-27a
16.6.3	Using Proxies to Obtain Medical Records.....	16-27a
<b>16.7</b>	<b>Follow-Up of Participants With Less Than Full Participation Status (Required).....</b>	<b>16-28</b>
16.7.1	Participants Who Have Stopped Intervention (CT) (Required).....	16-28
16.7.2	Participants on Partial Follow-up.....	16-28
	CT Participants (Required) 16-28	
	OS Participants (Required) 16-29	
16.7.3	Participants Who Are Lost to Follow-Up.....	16-29
16.7.4	Participants on No Follow-Up.....	16-29
16.7.5	Participants on Absolutely No Follow-Up (Required).....	16-29
<b>16.8</b>	<b>Non-Routine Contacts.....</b>	<b>16-30</b>
<b>16.9</b>	<b>Follow-Up Visits by Guest Participants.....</b>	<b>16-40</b>
<b>16.10</b>	<b>Guidelines for Contacts With Participants' Survivors.....</b>	<b>16-41</b>
16.10.1	WHI Expectations for Staff Contacts With a Participant's Survivor.....	16-41
16.10.2	General Considerations for <u>All CC Staff</u> .....	16-41
16.10.3	Considerations for <u>Staff Who Collected Medical History Information</u> from Survivors.....	16-43
16.10.4	Family or Proxy Requests for Information.....	16-44
<b>16.11</b>	<b>Guidelines for Participants With Cognitive Decline.....</b>	<b>16-45</b>
16.11.1	Identifying Potential Cognitive Decline in WHI Participants.....	16-45
16.11.2	Addressing Cognitive Decline Concerns.....	16-45
	Assessing Specific Concerns.....	16-47
	Carrying out Action Items.....	16-47
	Changing Level of Participation.....	16-47
16.11.3	Strategies for Managing a Participant's Cognitive Decline.....	16-48
<b>16.12</b>	<b>Procedures and Guidelines for HT/DM/CaD Pre-Closeout Contacts.....</b>	<b>16-49</b>
16.12.1	Introduction.....	16-49
16.12.2	Transition Discussion.....	16-49
16.12.3	Adherence and Retention Strategies.....	16-50
16.12.4	DM Adherence Motivational Postcard (for DM-I only).....	16-52

<b>16.13</b>	<b>WHI Close-out.....</b>	<b>16-53</b>
16.13.1	CT Close-out.....	16-53
	Close-out Mailing Packet.....	16-53
	Assemble Close-out Visit Materials Before the Close-out Visit.....	16-53
	Conducting the Close-out Visit.....	16-54
	Close-out Visit Procedures.....	16-54
	Activities for Participants Who Do Not Come to the Close-out Visit.....	16-57
	Ancillary Study Tasks at Close-out.....	16-57
16.13.2	OS Close-out.....	16-60
	Timing of the "Regular Annual OS Mailing" During the Year Preceding Close-out.....	16-60
	CCC Responsibilities for OS Close-out.....	16-61
	CC Responsibilities During OS Close-out (Required).....	16-61
	CC Data Collection for Non-Respondents to OS Close-out Mailings (Required).....	16-62
	OS BMD Scans at Bone Density (BMD) Sites.....	16-62
16.13.3	Proxy Close-out (CT and OS Participants).....	16-64
16.13.4	Close-out Events (CT and OS Participants).....	16-64
16.13.5	Outcomes.....	16-64
16.13.6	Data Management.....	16-64
16.13.7	Records Retention.....	16-64
16.13.8	Equipment.....	16-65
<b>16.14</b>	<b>WHI Extension Study and Supplemental Use Consents.....</b>	<b>16-66</b>
16.14.1	Obtaining Consents for CT and OS Participants.....	16-66
16.14.2	Extension Study Consent Collected in the CC.....	16-67
	Extension Study Talking Points.....	16-67
	Review of Extension Study Consent.....	16-68
	Signing of the Extension Study Consent.....	16-69
16.14.3	Supplemental Consent (for use of stored specimens) Collected in the CC.....	16-69
	Supplemental Consent Talking Points.....	16-69
	Review of Supplemental Consent.....	16-70
	Signing of the Supplemental Consent.....	16-71
16.14.4	Collecting the Consents by Mail.....	16-71
16.14.5	Obtaining Consent Forms from CT or OS Participants on Proxy Follow-up.....	16-71
16.14.6	Signing of the <i>Form 114 – WHI Genetic Studies Consent Status</i> .....	16-72
<b>16.15</b>	<b>Post Close-out DM-C Newsletter (for DM-C only).....</b>	<b>16-74</b>

## Figures

16.1	Cover Letter for OS Contact 1 (Year 1).....	16-31
16.2	Follow-Up Postcard for OS Contact 2.....	16-32
16.3	Cover Letter for OS Contacts 3/4 (Year 1).....	16-33
16.4	Suggested Script for OS Contact 5 Telephone Contact.....	16-34
16.5	Suggested Script for Proxy Telephone Contact.....	16-36
16.6	Sample Cover Letter for Proxy Contact.....	16-38
16.7	Postcard for Participants on No Follow-Up.....	16-39
16.8	Algorithm for Addressing Cognitive Decline Concerns.....	16-46
16.9	Dietary Adherence Motivational Postcard.....	16-52

## Tables

16.1	Time Limits for Collecting Tasks.....	16-18a
16.2	Follow-Up Clinical Examinations/Minimum Safety Requirements for HRT Participants.....	16-19
16.3	Options for WHI Task Completion.....	16-19a

16.4	CT Close-out Mailing Packet Materials .....	16-58
16.5	CT Thank You Packet Materials .....	16-59
16.6	Timing of OS Close-out Data Collection.....	16-60
16.7	OS Close-out Mailing Packet Materials (Mailed by CCC).....	16-65
16.8	OS Consent Packet Materials .....	16-73

---

## SECTION 17: RETENTION

---

<b>Introduction .....</b>	<b>17-1</b>
<b>17.1 General Activities to Promote Retention .....</b>	<b>17-2</b>
17.1.1 Clinical Center Facilities and Operations .....	17-2
CC Environment.....	17-2
Convenience and Accessibility .....	17-2
Time in Clinical Center.....	17-2
17.1.2 Clinical Center Staff.....	17-3
Participant-Staff Relationships.....	17-3
Retention Specialist .....	17-3
17.1.3 Participant Identification With WHI (Required).....	17-3
Routine Contacts.....	17-3
Involvement of Family Members .....	17-4
Membership Identification Cards .....	17-5
Participant Representative.....	17-5
CC Group Events and Activities .....	17-5
Health Information and Education.....	17-6
17.1.4 Tracking (Required).....	17-6
Tracking System for Study Visits .....	17-6
CC Visit Appointment Reminders .....	17-6
Thank You Cards Following CC Visits.....	17-7
Maintaining Up-to-Date Personal Information on Participants .....	17-7
Maintaining Complete and Deliverable Participant Addresses .....	17-7
17.1.5 Participant Newsletter (Required).....	17-8
Production and Distribution.....	17-8
Content .....	17-8
Updating Addresses for Undeliverable Newsletters .....	17-9
17.1.6 Retention Incentives (Required).....	17-9
Annual Incentives Provided by CCC.....	17-10
CC Incentives.....	17-10
Distributing Incentives.....	17-10
17.1.7 Media Relations and Handling Adverse Publicity.....	17-10
<b>17.2 Clinical Center Activities for Retention Challenges (Required).....</b>	<b>17-11</b>
17.2.1 Identifying Retention Challenges and Tracking Special Activities.....	17-11
17.2.2 Special Activities for HRT/CaD <u>Intervention</u> Retention Challenges .....	17-13
Identifying HRT and CaD Intervention Retention Challenges .....	17-13
Initiating Special Activities for HRT and CaD Retention Challenges (IAP).....	17-13
Documenting and Tracking Special Activities for HRT/CaD Retention Challenges .....	17-18
Ending Special Activities for HRT/CaD Retention Challenges.....	17-18
17.2.3 Special Activities for DM Intervention Retention Challenges.....	17-19
Identifying DM Intervention Retention Challenges .....	17-19
Initiating Special Activities for DM Intervention Retention Challenges.....	17-19
Documenting and Tracking Special Activities for DM Intervention Retention Challenges .....	17-19

17.2.4	Ending Special Activities for DM Intervention Retention Challenges .....	17-20
	Special Activities for <u>Follow-Up</u> Retention Challenges (CT and OS).....	17-20
	Identifying Follow-Up Retention Challenges .....	17-20
	Initiating Special Activities for Follow-Up Retention Challenges .....	17-20
	Documenting and Tracking Special Activities for Follow-Up Retention Challenges .....	17-20
	Ending Special Activities for Follow-Up Retention Challenges .....	17-21
<b>17.3</b>	<b>Locating "Hard to Find" Participants .....</b>	<b>17-22</b>
17.3.1	Initiating a Search to Locate Participant ( <i>Form 23</i> ) (Required for Vital Status Searches).....	17-22
17.3.2	Strategies to Locate "Hard to Find" Participants (Recommended).....	17-22
17.3.3	Ending the Search to Locate Participant (Required).....	17-23
17.3.4	Procedures for Study-Wide Vital Status Ascertainment (Required).....	17-24
17.3.5	Searches of the National Death Index.....	17-24b
<b>17.4</b>	<b>Changes in Participation Status.....</b>	<b>17-25</b>
17.4.1	Changing Intervention Status (Required) .....	17-25
17.4.2	Changing Follow-Up Status (Required).....	17-27
17.4.3	General Steps in Changing Participant Status .....	17-28
17.4.4	Retrieving Study Pills [HRT and CaD].....	17-29
17.4.5	Reactivation of Participants With Changes in Participation Status .....	17-29
	Purpose.....	17-29
	Eligibility for Reactivation.....	17-30
	Reactivation Approaches (Recommended).....	17-30
	Reactivation From No Follow-Up or Stop Intervention Status .....	17-30
	Reactivation From No Follow-Up Phone Contacts .....	17-31
	Reactivation From No Contact Mailing (Recommended).....	17-31
	Reactivation Visit (Recommended).....	17-32
	Preparation (Recommended).....	17-32
	Conducting the Reactivation Visit (Recommended).....	17-32
<b>17.5</b>	<b>Transfer of Participants Between Clinical Centers .....</b>	<b>17-33</b>
17.5.1	Transfer Team Procedures (Originating CC).....	17-35
17.5.2	Transfer Team Procedures (Receiving CC).....	17-37
17.5.3	Procedures to Finalize Transfer (Originating/Receiving CC).....	17-37b
17.5.4	CCC Transfer Procedures.....	17-37b
17.5.5	Ancillary Study Transfers.....	17-37b
<b>17.6</b>	<b>Participants Who Move to Area Without Local CC.....</b>	<b>17-37e</b>

## Figures

17.1	Sample Form to Track Contact Attempts.....	17-38
17.2	Intensive Adherence Program Checklist .....	17-40
17.3	IAP Participant Call Record .....	17-41
17.4	Daily Adherence Diary .....	17-42
17.5	Transfer Checklist .....	17-42a

## Tables

17.1	Summary of Retention Activities .....	17-43
17.2	Summary of Clinical Center Activities for Retention Challenges.....	17-49
17.3	Reasons for Poor Retention and/or Adherence .....	17-50
17.4	Strategies to Retain Full Participation in CT and OS .....	17-51
17.5	Strategies for Adherence to CT Intervention .....	17-53
17.6	Examples of Retention Strategies.....	17-54

---

## SECTION 18: DATA MANAGEMENT

---

<b>Introduction .....</b>	<b>18-1</b>
<b>18.1 Form Flow.....</b>	<b>18-2</b>
18.1.1 Specimen Tracking .....	18-2
18.1.2 Follow-Up Visits .....	18-3
<b>18.2 Data Collection .....</b>	<b>18-4</b>
18.2.1 Data Collection Forms .....	18-4
18.2.2 Recording Data on Forms .....	18-4
Recording "Unknown" Responses on Forms.....	18-5
Recording Data on Mark-Sense Forms .....	18-5
18.2.3 Review of Forms .....	18-6
18.2.4 Editing Forms .....	18-6
Editing Key-Entry Forms.....	18-6
Editing Mark-Sense Forms.....	18-7
<b>18.3 Data Entry .....</b>	<b>18-8</b>
18.3.1 Data Entry Workspace .....	18-8
18.3.2 Direct Data Entry .....	18-8
18.3.3 Scanning of Mark-Sense Forms .....	18-8
18.3.4 Key-Entry .....	18-9
Key-Entry of Specimen/Test Forms .....	18-10
18.3.5 Data Security.....	18-10
<b>18.4 Quality Assurance .....</b>	<b>18-11</b>

---

## SECTION 19: QUALITY ASSURANCE

---

<b>19.1 Moved to Vol. 7 - Quality Assurance.....</b>	<b>19-1</b>
--	-------------

---

## SECTION 20: SPECIAL POPULATIONS CONSIDERATIONS

---

<b>Introduction .....</b>	<b>20-1</b>
<b>20.1 Special Considerations in Cross-Cultural Counseling and Interaction.....</b>	<b>20-2</b>
20.1.1 Cultural Values .....	20-2
20.1.2 Health Beliefs .....	20-2
20.1.3 Approaches to Dietary Change .....	20-3
20.1.4 Non-Verbal Communication.....	20-3
20.1.5 Getting Accurate Information.....	20-4
20.1.6 Preparing for Cross-Cultural Counseling or Interaction.....	20-5
20.1.7 Enhancing Communication .....	20-5
20.1.8 Promoting Positive Change .....	20-5
<b>20.2 Working with Older Women, Ethnic Minorities, and Women with Special Needs .....</b>	<b>20-6</b>
20.2.1 Older Women .....	20-6
Health and Functional Impairments.....	20-6
Personality and Motivational Factors.....	20-6

	Cohort Differences (Life Experience Effects) .....	20-7
20.2.2	Women From Minority Groups .....	20-7
	Ethnic/Racial Sensitivity .....	20-7
	Personality Motivational Factors .....	20-8
	Cohort Differences (Life Experience Effects) .....	20-9
20.2.3	African-American (Black).....	20-9
20.2.4	Hispanic .....	20-9
20.2.5	Native American .....	20-10
20.2.6	Asian .....	20-11
20.2.7	Women With Special Needs.....	20-11
<b>20.3</b>	<b>Guidelines for Translating Documents Into Spanish.....</b>	<b>20-13</b>

---

**APPENDICES**

---

**A: INDEX**

- Not included in Vol. 2 of the Manual at time of second printing (September, 1994)

**B: ABBREVIATIONS, TERMS AND DEFINITIONS**

<b>B.1</b>	<b>List of Abbreviations .....</b>	<b>B-1</b>
------------	------------------------------------	------------

<b>B.2</b>	<b>List of Terms and Definitions .....</b>	<b>B-4</b>
------------	--	------------

**C: WOMEN'S HEALTH INITIATIVE DIRECTORY**

- Last updated July 1996

**D: SUMMARY OF BULLETINS IN ALL VOLUMES**

**E: MODEL CC PRINTED MATERIALS**

**Figures**

<b>E.1</b>	<b>Community/Health Care Provider Materials .....</b>	<b>E-1</b>
------------	---	------------

E.1.1	Model Letter to Community Health Care Providers and Physicians .....	E-1
-------	--	-----

E.1.2	Model WHI Fact Sheet.....	E-2
-------	---------------------------	-----

E.1.3	Model National Press Release.....	E-3
-------	-----------------------------------	-----

E.1.4	Model Letter to HRT Participant Health Care Provider.....	E-4
-------	---	-----

E.1.5	Model Letter Sent With Chart Labels to Health Care Providers .....	E-5a
-------	--	------

E.1.6	Model Primary Care Provider Letter for HERS Information .....	E-5c
-------	---	------

E.1.7	Model Primary Care Provider Letter for Unblinding .....	E-5d
-------	---	------

<b>E.2</b>	<b>Participant Recruitment Materials.....</b>	<b>E-6</b>
------------	---	------------

E.2.1	Model Initial Contact Letter.....	E-6
-------	-----------------------------------	-----

E.2.2	Model Interest Survey.....	E-7
-------	----------------------------	-----

E.2.3	Model Prescreen.....	E-8
-------	----------------------	-----

E.2.4	Model How to Fill Out <i>Form 2 – Eligibility Screen</i> .....	E-9
-------	--	-----

E.2.5	Model CaD Recruitment Letter.....	E-9a
-------	-----------------------------------	------

<b>E.3</b>	<b>Participant Contact Materials.....</b>	<b>E-10</b>
------------	---	-------------

E.3.1	Model SVI Reminder Letter.....	E-10
-------	--------------------------------	------

E.3.2	Model Appointment Card.....	E-11
E.3.3	Model Ineligible Letter.....	E-12
E.3.4	Model Follow-Up Appointment Reminder Letter.....	E-13
E.3.5	Model No-Contact Mailing Postcard.....	E-14
E.3.6	Model Cover Letter to Include in <i>Form 49 – E+P Survey Mailing</i> .....	E-14a
<b>E.4</b>	<b>Clinical Center Contact Materials.....</b>	<b>E-15</b>
E.4.1	Model SV0 Checklist.....	E-15
E.4.2	Model SV1 Checklist.....	E-16
E.4.3	Model SV2 Checklist.....	E-19
E.4.4	Model SV3 Checklist.....	E-22
E.4.5	Model OS Checklist.....	E-24
E.4.6	Model Semi-Annual Checklist (CT).....	E-24a
E.4.7	Model Annual (CT) or Third-Year (OS) Visit Checklist.....	E-24b
<b>E.5</b>	<b>Participant Handouts.....</b>	<b>E-25</b>
E.5.1	Model General Medical Release Form.....	E-25
E.5.2	Model HRT Endometrial Aspiration.....	E-26
E.5.3	Model HRT – After Your Endometrial Aspiration.....	E-27
E.5.4	Model HRT Study Pills Instruction Sheet.....	E-28
E.5.5	Model HRT Symptoms Brochure.....	E-29
E.5.6	Model CaD Study Pill Instruction Sheet.....	E-31
E.5.7	Model Request for Medical Information.....	E-32
E.5.8	Model Antibiotic and Medication Allergies Questionnaire (HRT Participants With Uteri).....	E-33
E.5.9	Model Statement for Non-Child-Resistant Cap.....	E-34
E.5.10	Model Summary of Changes in the Dietary Part of the WHI and in the Dietary Part Consent Form.....	E-35
E.5.11	Model Invitation to Join the Calcium and Vitamin D Program of the WHI!.....	E-36
E.5.12	Privacy Act Notification Statement.....	E-36b
E.5.13	Model Summary of Changes for Participants in the 4DFR Subsample.....	E-36c
E.5.14	Model Better Balance in Eating Patterns.....	E-36d
E.5.15	Model Fact Sheet – Learning About Fat.....	E-36e
E.5.16	Participant Certificate of Appreciation.....	E-36g
<b>E.6</b>	<b>OS Participant Contact Materials.....</b>	<b>E-37</b>
E.6.1	Model Contact Letter for Women Ineligible for CT Between Screening Visits.....	E-37
E.6.2	Model Follow-Up Thank You/Reminder Postcard.....	E-39
E.6.3	Model Contact Letter for Women Screened Before September 1, 1994.....	E-40
E.6.4	List of Questionnaire Descriptions for Inclusion With OS Contact Letters.....	E-42
<b>E.7</b>	<b>Close-out Materials.....</b>	<b>E-43</b>
E.7.1	Model Close-out Visit Appointment Reminder Letter.....	E-43
E.7.2	Model Cover Letter - Extension Study Consent (Non-HT).....	E-45
E.7.3	Model Extension Study Consent (Non-HT).....	E-46
E.7.4	Model Cover Letter - Extension Study Consent (HT).....	E-51
E.7.5	Model Extension Study Consent (HT).....	E-52
E.7.6	Model Cover Letter - Supplemental Consent.....	E-57
E.7.7	Model Supplemental Consent.....	E-58
E.7.8	Model Thank You Packet Cover Letter.....	E-62
E.7.9	Model PI Thank You Letter.....	E-63
E.7.10	Model Cover Letter for Mailed Consent Packet.....	E-64
E.7.11	Model WHI Consent Summary Worksheet.....	E-65

## **F: REQUIRED CC PRINTED MATERIALS**



**F.1 Consent Material.....F-1**

F.1.1 Video Information Handout - WHI Introduction..... F-1

F.1.2 Video Information Handout - WHI Dietary Program..... F-3

F.1.3 Video Information Handout - WHI Hormone Replacement Program (For Eligible Women With a Uterus)..... F-5

F.1.4 Video Information Handout - WHI Hormone Replacement Program (For Eligible Women Without a Uterus)..... F-7

**F.2 Welcome Handouts.....F-9**

F.2.1 Welcome to the Women's Health Initiative! ..... F-9

F.2.2 Welcome to the Dietary Change Group of the WHI!..... F-11

F.2.3 Welcome to the Comparison Group of the WHI Dietary Program! ..... F-13

F.2.4 Welcome to the Hormone Replacement Program of the WHI!..... F-15

F.2.5 CaD Information Sheet ..... F-17

F.2.6 Welcome to the Observational Study of the WHI! (Non-Bone Density Sites)..... F-19

F.2.7 Welcome to the Observational Study of the WHI! (Bone Density Sites)..... F-21

**F.3 Participant Handouts ..... F-23**

F.3.1 About Calcium in Your Diet..... F-23

F.3.2 Hormone Program Handbook..... F-25

F.3.3 Keeping Track of Goals ..... F-45

F.3.4 Eating Pattern Changes ..... F-47

F.3.5 What You Should Know About Deep Vein Thrombosis (DVT) [For Women in HRT Screening Process]..... F-49

F.3.6 What You Should Know About Deep Vein Thrombosis (DVT) [For Women Randomized to HRT] ..... F-51

F.3.7.1 WHI Quick Scan Guidelines for Nutritionists ..... 5-53

F.3.7.2 WHI Quick Scan Guidelines for Participants ..... F-54

F.3.7.3 WHI Quick Scan ..... F-55

WHI Quick Scan (Continued)..... F-56

F.3.8 WHI Picture Tracker Instructions..... F-57

WHI Picture Tracker ..... F-58

F.3.9 WHI Update - What You Should Know About the "HERS" Study..... F-59

F.3.10 WHI Update - What You Should Know About : SERMs ..... F-60a

F.3.11 WHI Update - What You Should Know About: Osteoporosis ..... F-60c

F.3.12 WHI Update - WHI Today ..... F-60e

F.3.13 WHI Update - Health Follow-up by Proxy ..... F-60g

F.3.14 Proxy Letter ..... F-60i

F.3.15 CaD Handbook..... F-61

**F.4 Provider Materials ..... F-76**

F.4.1 Chart Labels ..... F-76

**F.5 Close-out Materials.....F-77**

F.5.1 Health Screening Guidelines Handouts ..... F-77

F.5.2 Certificate of Appreciation..... F-78

F.5.3 WHI Dietary Study Summary ..... F-79

F.5.4 WHI Dietary Study Frequently Asked Questions ..... F-81

F.5.5 CaD Fact Sheet ..... F-84

**G: RESOURCE MATERIALS**

**G.1 Questions and Answers: .....G-1**

G.1.1 Calcium & Vitamin D Trial (For CC Staff)..... G-1

G.1.2 HRT (For CC Staff)..... G-5

G.1.3 Venous Thromboembolism (Deep Vein Thrombosis [DVT] and Pulmonary Embolism [PE])..... G-7

G.1.4 Bone Density (For CC Staff)..... G-9

G.1.5	Clinical Trials (For CC Staff) .....	G-12
G.1.6	The Heart and Estrogen/Progestin Replacement Study (HERS).....	G-12a
<b>G.2</b>	<b>Hot Tips .....</b>	<b>G-12f</b>
G.2.1	Clinic Management .....	G-12f
G.2.2	CC Staffing .....	G-12f
G.2.3	Facilities .....	G-14
G.2.4	Recruitment .....	G-14
G.2.5	Participant Scheduling.....	G-22d
G.2.6	Clinic Flow.....	G-22e
G.2.7	Data Management .....	G-22g
G.2.8	Outcomes.....	G-22h
G.2.9	Retention .....	G-22h
G.2.10	Adherence.....	G-22h
G.2.11	Appendix – Examples of Successful Recruitment Strategies.....	G-22u
G.2.12	Appendix - Hot Tips for Adherence and Retention Booklet .....	G22x
<b>G.3</b>	<b>WHI Press Materials.....</b>	<b>G-23</b>
G.3.1	Backgrounder.....	G-23
G.3.2	Women’s Health Initiative Clinical Centers (Map).....	G-25
G.3.3	Hormone Replacement Therapy Study Fact Sheet .....	G-26
G.3.4	Dietary Modification Study Fact Sheet .....	G-28
G.3.5	Calcium/Vitamin D Supplementation Study .....	G-29
G.3.6	Observational Study .....	G-30
G.3.7	Women and Heart Disease .....	G-31
G.3.8	Women and Breast and Colorectal Cancer.....	G-32
G.3.9	Women and Osteoporosis .....	G-33
<b>G.4</b>	<b>Position Statements .....</b>	<b>G-34</b>
G.4.1	WHI Olestra Position Statement .....	G-34
G.4.2	Press Release from FDA and Proctor and Gamble About Olestra .....	G-34
G.4.3	Common Questions & Answers About Olean .....	G-38
<b>G.5</b>	<b>Motivation Enhancement .....</b>	<b>G-40</b>
G.5.1	Motivation Enhancement Training August 1999, WHI Intensive Intervention Protocol.....	G-40
G.5.2	Working With Special Populations Using the Motivational Enhancement.....	G-95
<b>G.6.</b>	<b>Health News Discussion.....</b>	<b>G-97</b>
G.6.1	Health News Discussion Guide.....	G-97
<b>G.7</b>	<b>Personalized Evaluation of Fat Intake (PEFI).....</b>	<b>G-99</b>
G.7.1	PEFI-Q Adjustment Questions.....	G-99
G.7.2	Tailored Messages for Top 10 Foods on PEFI-F .....	G-107
G.7.3	PEFI-F Samples .....	G-112
<b>G.8</b>	<b>Personalized Evaluation of Fat Intake 2003 (PEFI 2003).....</b>	<b>G-131</b>
G.8.1	PEFI 2003 Modifications to Tailored Messages for Top 10 Foods on PEFI-F .....	G-131
G.8.2	PEFI 2003 Materials.....	G-132
<b>G.9</b>	<b>Materials for a Required "Pre-Close-out Contact" with HT, CaD, and DM Participants .....</b>	<b>G-159</b>
G.9.1	WHI Timelines and Milestone Charts.....	G-159
G.9.2	Dear Dr. Letter and Information Sheet .....	G-164
G.9.3	Potential Questions and Answers During Pre-Closeout Contacts .....	G-166

## Figures

G.1	Fat Grams Reported on PEFI: Over Fat Gram Goal .....	G-113
-----	--	-------

G.2 Fat Grams Reported on PEFI: <Fat Gram Goal, but >15 Grams of Fat.....G-119

G.3 Fat Grams Reported on PEFI: <15 Grams of Fat.....G-125

G.4 PEFI 2003 - PEFI-Q Cover Letter/Instructions .....G-133

G.5 PEFI 2003 - PEFI-Q Request for Additional Information Letter.....G-136

G.6 PEFI 2003 - Sample PEFI-F: Over Fat Gram Goal.....G-138

G.7 PEFI 2003 - Sample PEFI-F: ≤ Fat Gram Goal, but ≥ 15 Grams of Fat.....G-144

G.8 PEFI 2003 - Sample PEFI-F: <15 Grams of Fat.....G-150

G.9 PEFI 2003 - Guide for Your PEFI Packet.....G-156

**Tables**

G.1 Response Weighing for Frequency of Use Adjustments.....G-99

G.2 Adjustment Questions: Type of Default and Specific Default Used .....G-102

G.3 PEFI-Q Line Item Information: Adjustment Questions Associated with Specific Lines &  
Fat Grams Associated with a Medium Serving Size.....G-103

G.4 Food Messages .....G-110

G.5 Modifications in 'Healthy Choice' Food Messages for PEFI 2003.....G-132

**H: CONSULTING GYNECOLOGIST HANDBOOK**

**Version 2 maintained in a separate binder at the CCs, labeled Vol. 2, Appendix H (October 2001).**